Showing 2341-2350 of 8876 results for "".
DWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aRegenerative Treatments in Dermatology
https://practicaldermatology.com/series/c-suite-chats/regenerative-treatments-in-dermatology/37707/John Aylworth, PhD, CEO and founder of Xytogen Biotech, talks about the growing demand for regenerative treatments in dermatology and new options for the treatment room.DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privDermwireTV: DermaRite Issues Recall for Several Hand Soaps
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermarite-issues-recall-for-several-hand-soaps/37113/In this episode, new research shows switching between interclass biologics may be safe and effective for psoriasis patients; DermaRite recalls 4 skin care products over contamination concerns; and awareness grows for generalized pustular psoriasis through a new global awareness campaign.DWTV Extra: DermLink Scholars Founder Dr. Kelly Frasier
https://practicaldermatology.com/series/dermwire-tv/DWTV-Extra-DermLink-Scholars-Founder-Dr-Kelly-Frasier/36554/DermLink Scholars Founder and CEO Kelly Frasier, DO, MS, CRC, and Alina G. Bridges, DO, FAAD, discuss the organization and its inaugural virtual conference Saturday, August 2. For more information, go to dermlinkscholars.com.Evaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/series/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin andFDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Procedural Management for HS
https://practicaldermatology.com/programs/practical-dermatology/procedural-management-for-hs/35891/Vivian Shi, MD, talks about procedural management for hidradenitis suppurativa and how to incorporate those procedures with medical management of the condition at Music City SCALE 2025.Rosacea Treatment Options and Strategies
https://practicaldermatology.com/programs/practical-dermatology/rosacea-treatment-options-and-strategies/35893/Joel L. Cohen, MD, FAAD, and Hilary Baldwin, MD, talk at Music City SCALE 2025 about the latest treatment options for rosacea and strategies for getting patient buy-in.Nail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.